Evidence presented in a new scientific research paper finds large reductions in covid-19 deaths are possible using ivermectin as a treatment – something not currently supported by government or Medsafe as it would mean using it ‘off-label’.
Findings published in June 2021 by PubMed show using ivermectin early may reduce the number of covid-19 patients progressing to severe disease. The apparent safety and low cost suggest that ivermectin is likely to have a significant impact on the SARS-CoV-2 pandemic globally.
The report’s authors say meta-analysis of 15 trials found ivermectin reduced risk of death compared with no ivermectin.
Low-certainty evidence found that ivermectin treatment reduced covid-19 infection by an average 86% (95% confidence interval 79%-91%).
Estimates for “improvement” and “deterioration” clearly favored ivermectin use, say the report’s authors.
Severe adverse events were rare among treatment trials and evidence of no difference was assessed as low certainty. Evidence on other secondary outcomes was very low certainty.
Medsafe has approved an arthritis drug as a covid-19 treatment – off-label.
The Pfizer vaccine is currently in the trial phase. The trial started in May 2021 and will conclude in July 2023. At which point data will be reviewed and results published as and when. The number of participants in the trial is 999 (correct: nine hundred and 99).
Below Joe Rogan explains how Ivermectin helped him beat a covid-19 infection, plus commentary by Russell Brand.